SCHEMBL656941

SCHEMBL656941

O=C(O)COc1ccc(OC(F)(F)F)cc1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.59
SMN1; SMN2 Q16637 2/20 0.58
ALDH1A1 P00352 3/20 0.55
PPARD Q03181 3/20 0.54
MAOB P27338 1/20 0.54
AOC3 Q16853 1/20 0.54
CYP1A2 P05177 1/20 0.54
CYP2C19 P33261 1/20 0.54
FFAR1 O14842 1/20 0.53
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
MAPT P10636 1/20 0.51
PTPN7 P35236 1/20 0.51
PTPN12 Q05209 1/20 0.51
MRGPRX4 Q96LA9 1/20 0.51
FFAR4 Q5NUL3 1/20 0.50
EPHX2 P34913 1/20 0.50
HRH3 Q9Y5N1 1/20 0.49
PPARA Q07869 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL339492 0.83 ALOX15 (0.81) ALOX15SMN1; SMN2ALDH1A1PPARDFFAR1
SCHEMBL12824120 0.83 ALDH1A1 (0.54) SMN1; SMN2ALDH1A1PPARDMAOBAOC3
SCHEMBL2171542 0.83 MAOB (0.57) SMN1; SMN2ALDH1A1MAOBAOC3CYP1A2
SCHEMBL118361 0.83 MAOB (0.53) SMN1; SMN2ALDH1A1MAOBAOC3CYP1A2
SCHEMBL10254673 0.82 LMNA (0.63) ALOX15PPARDCYP1A2CYP2C19FFAR1
SCHEMBL21294297 0.81 L3MBTL1 (0.61) PPARDFFAR1MRGPRX4FFAR4EPHX2
SCHEMBL2111994 0.81 PPARD (0.68) ALOX15SMN1; SMN2ALDH1A1PPARDMAOB
SCHEMBL5959355 0.81 PPARD (0.49) PPARDMAOBAOC3MRGPRX4PPARA
SCHEMBL13279565 0.80 MEN1 (0.63) SMN1; SMN2ALDH1A1PPARDMAOBAOC3
SCHEMBL9279028 0.80 ALDH1A1 (0.51) SMN1; SMN2ALDH1A1PPARDMAOBAOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115108905-B Method for producing (Z) -trifluoromethaneenol ester by copper-catalyzed regioselective olefination and trifluoromethylation of carboxylic acid 湖南大学 2025-04-08 CN claimed
US-7642344-B2 Methods and compositions for determining the sequence of nucleic acid molecules OPERON BIOTECHNOLOGIES, INC. (US) 2010-01-05 US claimed
EP-0992511-B1 Methods and compositions for determining the sequence of nucleic acid molecules OPERON BIOTECHNOLOGIES INC (US) 2009-03-11 EP claimed
US-20080009613-A1 Methods and compositions for determining the sequence of nucleic acid molecules OPERON BIOTECHNOLOGIES, INC. (US) 2008-01-10 US claimed
US-7247434-B2 Methods and compositions for determining the sequence of nucleic acid molecules OPERON BIOTECHNOLOGIES, INC. (US) 2007-07-24 US claimed
EP-0868535-B9 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES QIAGEN GENOMICS INC (US) 2007-05-09 EP claimed
EP-0868535-B2 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES QIAGEN GENOMICS INC (US) 2006-01-04 EP claimed
US-20040115694-A1 Methods and compositions for determining the sequence of nucleic acid molecules QIAGEN GENOMICS, INC. 2004-06-17 US claimed
EP-0990047-B1 METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY QIAGEN GENOMICS INC (US) 2003-05-14 EP claimed
US-20030077595-A1 Methods and compositions for enhancing sensitivity in the analysis of biological-based assays QIAGEN GENOMICS, INC. 2003-04-24 US claimed
EP-0990047-A2 METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID MOLECULES UTILIZING SIZING TECHNIQUES Rapigene, Inc. (US) 2000-04-05 EP claimed
US-6027890-A DETECTING LIGAND BINDING BY INCUBATING TAGGED MEMBERS WITH BIOLOGICAL SAMPLE, SEPARATING BOUND FROM UNBOUND MEMBERS, CLEAVING TAG, THEN DETECTING BY NON-FLUORESCENT SPECTROSCOPY OR POTENTIOMETRY RAPIGENE, INC. (US) 2000-02-22 US claimed
EP-0962464-A2 Methods and compositions for detecting binding of ligand pair using non-fluorescent label Rapigene, Inc. (US) 1999-12-08 EP claimed
WO-1999005319-A9 METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY RAPIGENE INC (US) 1999-06-17 WO claimed
WO-1999005319-A2 METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY RAPIGENE, INC. (US) 1999-02-04 WO claimed
EP-0868535-A2 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES Rapigene, Inc. (US) 1998-10-07 EP claimed
EP-0850320-A2 METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL DARWIN MOLECULAR CORPORATION (US) 1998-07-01 EP claimed
WO-1997027331-A9 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES 1997-10-09 WO claimed
WO-1997027331-A2 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES RAPIGENE, INC. (US) 1997-07-31 WO claimed
WO-1997027327-A2 METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL RAPIGENE, INC. (US) 1997-07-31 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009613-A1 Methods and compositions for determining the sequence of nucleic acid molecules CPSF6, RNMT, POLM ALOX15 3040/4885SMN1; SMN2 936/4885ALDH1A1 3332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.